T

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Retrieved on: 
Monday, May 15, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, CITES, Therapy, DC, NK, Perforin-1, Journal of Immunology, T, Walter, Poster, Cytokine, Gene, Pharmaceutical industry, Vaccine, Extractive metallurgy

The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.

Key Points: 
  • The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15.
  • “Equillium is developing EQ102 to selectively and synergistically block both IL-15 and IL-21 signaling, without affecting other gamma chain family members.
  • EQ102 is a multi-cytokine inhibitor that selectively blocks IL-15 and IL-21 signaling while preserving signaling of other γc family members.
  • Similarly, in pre-clinical studies, EQ102 has demonstrated the prevention of intestinal tissue damage in a humanized mouse model of gastrointestinal inflammation.

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

Retrieved on: 
Wednesday, April 19, 2023
Online, Molecule, Lymphoma, IL-12, Therapy, Natural killer T cell, Syngenic, Immunity, Toxicity, TCR, T, CD8, Patient, DOI, Mouse, Toxic epidermal necrolysis, Neoplasm, Tumor microenvironment, Vaccine, Medical imaging

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.

Key Points: 
  • WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.
  • mWTX-330 treatment expands unique T-cell receptor (TCR) clones and increases TCR clonality in the tumor microenvironment.
  • mWTX-330 treatment substantially increases mitochondrial activity in tumor infiltrating CD8+ T cells and NK Cells while reducing signs of exhaustion on CD8+ T cells.
  • The fully human WTX-330 INDUKINETM molecule is preferentially activated by primary human tumors.

Global Rich Communication Services Market Report 2023: Increasing Adoption of Mobile Service Subscribers Drives Growth

Retrieved on: 
Wednesday, April 19, 2023
Benchmark, SK Telecom, Maintenance, Communication, Travel, Orange Business Services, Tourism, AT, Health, Marketing, Telecommunications, Agriculture, COVID-19, VAS, Ericsson, Verizon Communications Inc. v. FCC (2002), Sale, RCS, PSTN, Organization, RAS, Deutsche Telekom, P2A, Telefónica, Growth, Public switched telephone network, BFSI, A2A, ZTE, SMS, T, Create, Geography, Network equipment provider, Fine chemical, Retail, Video game, Mobile phone, USD, Vodafone

The rich communication services market research report is one of a series of new reports that provides rich communication services market statistics, including rich communication services industry global market size, regional shares, competitors with an rich communication services market share, detailed rich communication services market segments, market trends and opportunities, and any further data you may need to thrive in the rich communication services industry.

Key Points: 
  • The rich communication services market research report is one of a series of new reports that provides rich communication services market statistics, including rich communication services industry global market size, regional shares, competitors with an rich communication services market share, detailed rich communication services market segments, market trends and opportunities, and any further data you may need to thrive in the rich communication services industry.
  • The increasing adoption of mobile service subscribers is expected to propel the growth of the rich communication services market.
  • Therefore, the increasing adoption of mobile service subscribers will drive the growth of the rich communication services market.
  • The rich communication services market consists of revenues earned by entities by providing A2A, P2P and P2A rich communication services.

Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Abstract (summary), AACR, Therapy, HER2, Cancer, Toxicity, Eftilagimod alpha, TAC, CD8, Patient, Mouse, Neoplasm, CD4, T, White, Safety, Pharmaceutical industry, Medical imaging, Vaccine

The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Key Points: 
  • The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
  • TAC01-HER2 obtained a disease control rate of 67% in heavily pretreated patients with solid tumors in patients who failed all standard of care therapies.
  • In a 5-day in vitro potency assay, patient-derived products showed effective tumor cell killing response similar to healthy-donor derived TAC T cells.
  • HER2-TAC γδ (gamma/delta) T cells selectively react to and kill HER2-expressing tumor cells in co-culture at low effector-to-target ratios, indicating strong functionality.

United States Complete Video Library Directory 2023: Complete Bibliographic Information on the Thousands of Video Options Available for Public, Community, and Academic Libraries - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Education, Technology, Audio, Video, Other Education, Anthropology, O, C Series Index, Index, Motion, Emmy Awards, VSDA, Yoga, Word processor, Directory, Running Time, Ballad & Pop Hits – The Complete Video Collection, British Academy Television Award for Best Entertainment Performance, Research, Medical Subject Headings, History, MPAA, ISBN, TVyNovelas Award for Best Program of Pay Television, Rocky, T, Wholesaling, Title, Publishing, Book, Abbreviation, Acupuncture, Volume 4

Since 1988, the Complete Video Directory has been the go-to source for complete bibliographic information on the thousands of video options available for public, community, and academic libraries across the nation.

Key Points: 
  • Since 1988, the Complete Video Directory has been the go-to source for complete bibliographic information on the thousands of video options available for public, community, and academic libraries across the nation.
  • 2023's Complete Video Directory is separated into four large volumes and contains fourteen thorough indexes.
  • All indexes (except the Awards Index) are presented alphabetically, then numerically, ensuring effortless research for the user.
  • Each entry in this Index contains similar bibliographic information to the entries in the Entertainment/Performance Title Index.

5G services market size to grow by USD 170.30 billion from 2021 to 2026: A descriptive analysis of parent market, five forces model, market dynamics, and segmentation - Technavio

Retrieved on: 
Thursday, December 15, 2022
Online, Maintenance, Verizon Communications, AT, Online and offline, Deutsche Telekom, Urban, BT, T, SK Telecom, MEA, Geography, Telephone, NTT, Orange S.A., Growth, Multimedia, Nippon Telegraph and Telephone, Beauty, Child, Vodafone, USD, Mobile phone

Vendor Landscape -The global 5G services market is fragmented, with the presence of several global as well as regional vendors.

Key Points: 
  • Vendor Landscape -The global 5G services market is fragmented, with the presence of several global as well as regional vendors.
  • This implies that the market in focus is characterized by growing R&Dand deployment of the 5G network.
  • The report provides actionable insights and an accurate estimation of the contribution of all regions to the growth of the global 5G services market.
  • Major Challenge - The 5G services market will face significant challenges due to the high deployment costs of 5G technology during the forecasted period.

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Retrieved on: 
Friday, November 11, 2022
Gamma, Chimeric antigen receptor T cell, U.S. Securities and Exchange Commission, FDA, SITC, NASDAQ, Adult, Weill Cornell Medicine, Risk, Maintenance, CP, Private Securities Litigation Reform Act, AM, ADCC, NCR Corporation, Neoplasm, Company, Memorial Sloan Kettering Cancer Center, Immunotherapy, CAR, Annual general meeting, Safety, Glossary, IPSC, Poster, Genetic engineering, COVID-19, Event, IND, Intellectual property, Society for Immunotherapy of Cancer, Therapy, Security (finance), CD16, GLOBE, Trastuzumab, B cell, Gene editing, Marketing, T, R, Society, Cancer, Century, Investigational New Drug, MSKCC, Memorial Hospital, Canadian Aviation Regulations, Ink, Research and development, Pharmaceutical industry, Vaccine, Medicine

PHILADELPHIA, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced preclinical data from the Company’s iPSC-based cell therapy platform were featured in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Additionally, the Company provided pipeline program updates ahead of its virtual Research and Development (R&D) Day taking place today, November 11, at 8:00 AM ET.

Key Points: 
  • Additionally, the Company provided pipeline program updates ahead of its virtual Research and Development (R&D) Day taking place today, November 11, at 8:00 AM ET.
  • We look forward to discussing these updates later this morning during our virtual R&D Day.
  • A copy of each poster presentation from the SITC Annual Meeting is available on Centurys website.
  • Preclinical data presented today demonstrate that iPSC-derived T cells derived from reprogrammed primary T cells can be efficiently engineered and produced with robust yield.

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Olive, CNRS, Clinical trial, Lung, NKS, T, Melanoma, SITC, INSERM, Society for Immunotherapy of Cancer, Granulocyte, Society, Cancer, MD, NK, Pembrolizumab, Therapy, Immunotherapy, CD8, Prostate, Doctor of Philosophy, Neoplasm, Degenerative disease, Research, Part, Patient, Annual general meeting, AACR, EMSO, Infection, Malignancy, Hematological Cancer Research Investment and Education Act, Antibody, Natural killer T cell, Colorectal cancer, LD, Immunology, Vaccine, Pharmaceutical industry, Butyrophilin, subfamily 1, member A1

The safety profile for the combination exhibited no dose-limiting toxicities in the first 3 dose cohorts and tolerability remained consistent without any new or increased adverse reactions.

Key Points: 
  • The safety profile for the combination exhibited no dose-limiting toxicities in the first 3 dose cohorts and tolerability remained consistent without any new or increased adverse reactions.
  • EVICTION-2 is a first-in-human, dose escalation (Part 1) and cohort expansion (Part 2) clinical trial evaluating ICT01 in combination with low dose subcutaneous IL-2.
  • BTN3A is essential for the activation of the anti-tumor immune response of 92 T cells.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Retrieved on: 
Wednesday, November 2, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, MAD, Risk, Adult, T, Inflammation, Peptide, MCP, CED, Degenerative disease, SEC, Department of Medicine – University of Pamplona, Research, HLA, Nasdaq, Disease, Alopecia areata, Feedback, Trial of the century, Department, EDGAR, Safety, Incidence, University, Private Securities Litigation Reform Act, Medicine, Cytokine, Patient, Itolizumab, Coeliac disease, Therapy, De novo, Forward-looking statement, JAK, Gene, Autoimmunity, Intestinal villus, Pharmaceutical industry, Medical imaging

Following the SAD/MAD portion of this study Equillium plans to evaluate the biological activity of EQ102 in subjects with celiac disease.

Key Points: 
  • Following the SAD/MAD portion of this study Equillium plans to evaluate the biological activity of EQ102 in subjects with celiac disease.
  • We believe this may be an optimal approach to treating patients with celiac disease, and we look forward to reporting initial clinical data from this study next year.
  • Following the MAD portion of this study, Part C of the study will evaluate the biological activity of EQ102 in subjects with celiac disease.
  • Equillium is currently enrolling patients in a Phase 1 study of EQ102, including healthy volunteers and celiac disease patients.

Syncell Selects $50,000 Grant Opportunity Winners for Spatial Proteomics

Retrieved on: 
Tuesday, October 25, 2022
Research, Medical Devices, Genetics, Biotechnology, Other Health, Health, General Health, Science, Oncology, Instituto de Medicina Molecular, Proteomics, Cilium, Frontotemporal dementia, T cell, Instituto Nacional de Medicina Genómica, Doctor of Philosophy, FTD, Mayo Clinic, Neurodegeneration, SFN, ICB, Neoplasm, Patient, Amyotrophic lateral sclerosis, Research, ALS, Immunotherapy, Technology, T, Immunological synapse, DRS, Protein, Proteome, GRASP, Pathology, Cellular, Biomarker, Organelle, Medical imaging

Syncell , pioneering innovative tools to accelerate the worlds understanding of proteomics, today announced Melissa Wren, Ph.D., & Dmytro Morderer, Ph.D., of the Dr. Wilfried Rossoll Lab at Mayo Clinic and Sofia Mensurado, Ph.D., of the Dr. Bruno Silva-Santos Lab at Instituto de Medicina Molecular (Lisbon) as the winners of its Spatial Proteomics Grant Opportunity Award.

Key Points: 
  • Syncell , pioneering innovative tools to accelerate the worlds understanding of proteomics, today announced Melissa Wren, Ph.D., & Dmytro Morderer, Ph.D., of the Dr. Wilfried Rossoll Lab at Mayo Clinic and Sofia Mensurado, Ph.D., of the Dr. Bruno Silva-Santos Lab at Instituto de Medicina Molecular (Lisbon) as the winners of its Spatial Proteomics Grant Opportunity Award.
  • Each receives early access to the Microscoop system for in situ spatial protein biomarker discovery, a sample-to-result spatial proteomics service valued up to $50,000.
  • The current bio-imaging-based spatial proteomics tools require using a preselected antibody panel to study the expression of these selected proteins.
  • Its pioneering Microscoop technology enables spatial protein biomarker discovery, making de novo subcellular spatial proteomics feasible for the first time.